

.....
(Original Signature of Member)

115TH CONGRESS
2D SESSION

H. R. _____

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

IN THE HOUSE OF REPRESENTATIVES

Mr. LANCE introduced the following bill; which was referred to the Committee
on _____

A BILL

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Eliminating Opioid Re-
5 lated Infectious Diseases Act of 2018”.

1 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**
2 **OF SURVEILLANCE AND EDUCATION RE-**
3 **GARDING INFECTIONS ASSOCIATED WITH IN-**
4 **JECTION DRUG USE.**

5 Section 317N of the Public Health Service Act (42
6 U.S.C. 247b–15) is amended to read as follows:

7 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**
8 **INFECTIONS ASSOCIATED WITH INJECTION**
9 **DRUG USE.**

10 “(a) IN GENERAL.—The Secretary, acting through
11 the Director of the Centers for Disease Control and Pre-
12 vention, may (directly and through grants to public and
13 nonprofit private entities) provide for programs to carry
14 out the following activities:

15 “(1) To cooperate with the States in imple-
16 menting a surveillance system to determine the inci-
17 dence of infections associated with injection drug use
18 and to assist the States in determining the preva-
19 lence of such infections, including the reporting of
20 chronic hepatitis C virus and human immuno-
21 deficiency virus cases.

22 “(2) To identify, counsel, and offer testing to
23 individuals who are at risk of infections as a result
24 of injection drug use, receiving blood transfusions
25 prior to July 1992, or other risk factors.

1 “(3) To provide appropriate referrals for coun-
2 seling, testing, and medical treatment of individuals
3 identified under paragraph (2) and to ensure, to the
4 extent practicable, the provision of appropriate fol-
5 low-up services.

6 “(4) To develop and disseminate public infor-
7 mation and education programs for the detection
8 and control of infections associated with injection
9 drug use, with priority given to high-risk populations
10 as determined by the Secretary.

11 “(5) To improve the education, training, and
12 skills of health professionals in the detection and
13 control of infections associated with injection drug
14 use, with priority given to substance use disorder
15 treatment providers, pediatricians, other primary
16 care providers, and obstetrician-gynecologists.

17 “(b) LABORATORY PROCEDURES.—The Secretary
18 may (directly and through grants to public and nonprofit
19 private entities) carry out programs to provide for im-
20 provements in the quality of clinical-laboratory procedures
21 regarding infections associated with injection drug use.

22 “(c) DEFINITIONS.—In this section, the term ‘injec-
23 tion drug use’ means—

1 “(1) intravenous administration of a substance
2 in schedule I under section 202 of the Controlled
3 Substances Act;

4 “(2) intravenous administration of a substance
5 in schedule II, III, IV, or V under section 202 of the
6 Controlled Substances Act that has not been ap-
7 proved for intravenous use under—

8 “(A) section 505 of the Federal Food,
9 Drug and Cosmetic Act; or

10 “(B) section 351 of the Public Health
11 Service Act; or

12 “(3) intravenous administration of a substance
13 in schedule II, III, IV, or V under section 202 of the
14 Controlled Substances Act that has not been pre-
15 scribed to the person using the substance.

16 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
17 purpose of carrying out this section, there are authorized
18 to be appropriated \$40,000,000 for each of the fiscal years
19 2019 through 2023.”.